Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Link opens in a new tab
Search content at Penn State
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Cross-protective responses to human papillomavirus infection
N. D. Christensen
, C. E. Bounds
Department of Pathology and Laboratory Medicine
Division of Experimental Pathology
Penn State Cancer Institute
Cancer Institute, Mechanisms of Carcinogenesis
Center for Cannabis and Natural Product Pharmaceuticals (CCNPP)
Department of Cell and Biological Systems
Research output
:
Contribution to journal
›
Review article
›
peer-review
3
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Cross-protective responses to human papillomavirus infection'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Anogenital
25%
Cause of Death
25%
Cervarix
25%
Cervical Cancer
25%
Clinical Trials
25%
Cross-protection
50%
Etiology
25%
Gardasil
25%
Head-and-neck
25%
Head-and-neck Cancer
25%
High-risk Human Papillomavirus (HR-HPV)
25%
HPV16
50%
Human Papillomavirus 6
25%
Human Papillomavirus Types
100%
Human Papillomavirus Vaccine
25%
Immunization
25%
Least Developed Countries
25%
Neutralizing Antibodies
25%
Oncogenic Human Papillomavirus
25%
Papillomavirus Infections
100%
Particle-based
25%
Protective Response
100%
Type-specific
25%
Virus-like
100%
Medicine and Dentistry
Cancer
20%
Cervical Cancer
20%
Clinical Trial
20%
Coat Protein
20%
Human Papillomavirus Type 11
20%
Human Papillomavirus Type 16
20%
Human Papillomavirus Type 18
20%
Human Papillomavirus Type 6
20%
Neck
20%
Neutralizing Antibody
20%
Papillomavirus Infection
100%
Virus Like Agent
40%
Wart Virus
100%
Wart Virus Vaccine
60%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
20%
Coat Protein
20%
Human Papillomavirus
100%
Human Papillomavirus Type 11
20%
Human Papillomavirus Type 16
20%
Human Papillomavirus Type 18
20%
Human Papillomavirus Type 6
20%
Neutralizing Antibody
20%
Papillomavirus Infection
100%
Uterine Cervix Cancer
20%
Virus Like Agent
40%
Virus Like Particle Vaccine
40%
Wart Virus Vaccine
60%